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Antisense oligonucleotides (AO) are short (typically
13–20 bases in length) sequences of single-stranded
DNA or RNA complementary to expressed genes and
are chemically modiﬁed to protect them from enzymatic
breakdown. They are designed to hybridise by Watson–
Crick base pairing with mRNA transcripts encoding
proteins of interest and in this way ‘silence’ the expres-
sion of that particular gene and subsequently its protein
product. The earliest attempt to inhibit gene expression
using AO was reported in 1978. The Rous sarcoma
virus was downregulated when exposed to a 13-base
oligonucleotide complementary to the 30reiterated
terminal sequences in a chick embryo ﬁbroblast. Tech-
nology was developed in the early 1980s for automated
synthesis of oligonucleotides with appropriate modiﬁ-
cations of the backbones to protect against nuclease
digestion and breakdown and greatly prolonging the
duration of eﬀect. With the great economy of scale, it
has opened up the prospect of harnessing ‘gene silenc-
ing’, by synthetic oligonucleotides as a therapeutic tool
for cancer. However, during the development of AO
therapy, there have been a number of design and devel-
opment problems to overcome.
1.1. Speciﬁcity of antisense oligonucleotides
mRNA has a three-dimensional tertiary structure that
essentially enables the molecule to fold back onto itself.
The result is that only certain areas with the mRNA
molecule are accessible to AO. Any AO outside these
accessible sites will not be functional due to their inher-
ent inability to bind to the mRNA. In order to identify
accessible sites, there are two essentially empiricalapproaches that can be used. The most elegant has been
developed by Prof. Southern and involves the use of
DNA ‘chip’ technology. AOs are directly synthesised
onto a glass slide with a complete representation of
consecutive nucleotide sequences singly or in groups of
2–20. The target RNA is labelled with radioactive
material and hybridised to the ‘chip’. The area of
strongest radioactive signal represents the areas of
optimal AO binding and deﬁnes the accessible sites in
the tertiary mRNA molecule. The second method uses
random libraries of AOs and looks for sites of mRNA
cleavage with the RNAseH enzyme. Prior to these
approaches for enzyme selection, many AOs were
selected randomly and many never demonstrated eﬀec-
tive downregulation of the target protein. Essentially,
these were ineﬀective AOs of no therapeutic use. It can-
not be overstressed how important it is to select an AO
that has the capacity to bind strongly to the target
mRNA. Without this ability, the eﬀect of the AO cannot
be attributed to an antisense action. Such molecules have
contributed to the early scepticism concerning antisense
therapy.
1.2. Metabolism and pharmacokinetics
The backbone of AO need to be modiﬁed from the
oxygen (phosphorodiester) atom to an alternative such
as the sulphur atom phosphorothioate (PS) in order to
confer resistance to nuclease degradation. There are
now a number of modiﬁcations although only the PS
modiﬁcation has been used extensively in human clinical
studies.
The PS modiﬁcation does cause some non-speciﬁc
inhibition of cell growth and non-sequence dependent
toxicities at higher doses, due in part to the strong
protein binding related to the sulphur molecules.
The pharmacokinetics of PS molecules have been
extensively studied. They are strongly protein-bound
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administered as infusions subcutaneously or intrave-
nously. Thirty percent of the dose is excreted in the
urine within 24 h; however, there are detectable levels
in most tissues in excess of 48 h, with only 15–50%
degradation. Blood and plasma clearance has a terminal
half life in excess of 40–60 h. The use of slow-release
pumps will prolong the bioavailability of the molecule
and increase steady-state levels. The PS molecules are
found at their highest levels within the liver, kidney,
bone marrow, skeletal muscle and skin; however, there
is no signiﬁcant crossing of the blood–brain barrier.
Toxicities are in general minimal below a dose of 6
mg/kg/day in humans for PS molecules; however, above
this dose, toxicites related to the phosphorothioate
backbone are seen and include reversible thrombocyto-
paenia and mild hyperglycaemia. Mild skin irritation
may also be seen with subcutaneous infusions at the site
of injection. Second-generation backbone chemistries
may, in part, reduce these toxicities.
1.3. How eﬀective is antisense?
There have been a number of false dawns with AOs in
part due to the recognised inadequacies already
described (nuclease degradation, chemistry, puriﬁcation,
cost, delivery and cellular bioavailability) and poor
sequence speciﬁcity. The latter has probably been one
of the major shortcomings. However, additional non-
speciﬁc sequence eﬀects can also occur. For example, a
succession of four guanosines in the AO molecule
may result in the formation of higher order structures
that will inhibit cell proliferation, while certain CpG
motifs will result in B-cell and NK-cell stimulation
with the release of cytokines such as TNF and inter-
feron.
Despite some of these non-speciﬁc eﬀects, it is
becoming clear that an AO that shows speciﬁc binding
to the target mRNA, cleaves it in the presence of
RNAseH and causes a reduction in the target protein, is
an eﬀective AO for therapy.1.4. Antisense targets for cancer
There are a host of targets that have been investigated
for anticancer therapy, some of which have been taken
to the clinic (see Table 1). These include Bcl-2, NF-KB
(p65), c-myb, c-myc, ERBB2, jun, fos, Ha-ras, Ki-ras,
DNA methyltransferase, PKA, C-raf kinase, mdm2 and
PKC-a. The assumption is that these will be key mol-
ecules in the process of tumorigenesis. The aim is to
alter the tumour-cell kinetics, to reduce tumour-cell
growth or sensitise to chemotherapeutic agents. Much
of the therapeutic approach to antisense therapy is well
illustrated by the Bcl-2 AO.
1.5. Bcl-2 as an antisense target
Many malignant cells have an inherent resistance to
chemotherapy due to the abnormal expression of the
antiapoptosis genes, of which Bcl-2 is a prominent
member. It has been the aim of Bcl-2 antisense oligo-
nucleotide (AS) therapy to reduce Bcl-2 protein in order
to overcome this resistance. Lymphoma associated with
the t(14;18) translocation (classically follicular lym-
phoma) and deregulated expression of the Bcl-2 gene,
conferring chemoresistance and subsequent protection
against cell death, is a logical target for AO. It is the
presence of increased Bcl-2 levels that confers a worse
prognosis by preventing apoptosis. This occurs at the
level of the mitochondria, by preventing the loss of
membrane potential and susequent activation of cas-
pases (predominantly caspase 3). Blocking Bcl-2 pro-
duction should bring about the death of the cell by
reversing this process. Non-sequence-related eﬀects
have caused much scepticism following initial enthu-
siasm for antisense therapy; however, an increased
understanding of these additional oligonucleotide prop-
erties has led to a number of emerging therapeutic AO
molecules for clinical use, working through a true anti-
sense downregulation of the target gene and protein.
This includes Bcl-2 AO (G3139 now known as ‘Gena-Table 1
Antisense oligonucleotides in clinical trials for oncologyTarget Tumor Route Phase Sponsorc-myb (LR-3001) CML IV 1 Lynxbcl-2 (G3139) NHL SC/IV 2 GentaLeukaemia (CLL/AML) 2Prostate 2Melanoma 3Myeloma 2PKA (GEM 231) Solid tumours IV 1 HybridonHa-ras (ISIS 2503) Solid tumours IV 1 IsisPKC- (ISIS 3521) Solid tumours IV 2 Isisc-raf kinase (ISIS 5132) Solid tumours IV 2 Isis/Novartis20 F.E. Cotter / EJC Supplements Vol 1 No. 2 (2003) 19–27
sense’ developed in collaboration with Genta, USA, an
antisenses research company), with phase I–III studies
commenced in the ﬁeld of cancer.2. Bcl-2 antisense oligonucleotide G3139: preclinical
studies
2.1. Target selection
Sequences targeted to the RNA loop structures show
logerithmically greater hybridisation than those in the
areas ﬂanking the loop [1]. The initiating codon of
mRNA, the AUG start site, is the area from which
protein synthesis is initiated. AO targeted to contain
complementary sequences to this area are most fre-
quently used in antisense experiments [2,3]. Such a site
was targeted for the Bcl-2 AO and proved useful, as
determined by its ability to bind speciﬁcally to Bcl-2
RNA in a cell-free system, downregulate Bcl-2 protein
and induce apoptosis in lymphoma cell lines. Oligo-
nucleotide length is important. Two useful AO of 18
(G3139) and 20 bases (G3854) were initially studied,
and both showed good intracellular internalisation. The
shorter oligonucleotide was developed further for clin-
ical use. Changing the linking molecule with the PS [4],
where sulphur atoms replace oxygen, was accomplished
to confers resistant to nuclease enzymes. To date, the in
vivo phase I and II human studies have all been based
on PS molecules and this is the molecule of choice for
current AO anticancer research.
2.2. Sequence-speciﬁcity for Bcl-2 antisense
The aim for antisense researchers is to show that an
AO targeted against a gene downregulates that gene in a
sequence-speciﬁc manner with no other eﬀects. It fol-
lows that all antisense experiments must be interpreted
with adequate reference to control parameters. Primarily,
it is essential to investigate the possibility of the AO hav-
ing a non-sequence-speciﬁc eﬀect, which would negate its
use for a true ‘gene silencing’ strategy. Whatever the
mechanism, the important consideration in assessing
antisense eﬀects is to establish sequence speciﬁcity of the
AO against control oligomers, and to demonstrate a
decrease in the amount of protein produced by the gene
targeted. This has been demonstrated for G3139 and
G3854 using both sense and nonsense controls. Down-
regulation of the Bcl-2 protein was demonstrated at 72 h
onwards in lymphoma cells with the t(14;18) transloca-
tion with antisense oligonucleotides, but not the control
sense and nonsense oligonucleotides [5]. The result is in
keeping with the Bcl-2 protein having a relatively long
half-life. The eﬀect was speciﬁc to cell lines dependent
on Bcl-2 for survival. No non-speciﬁc antiproliferative
eﬀects were seen [5].2.3. Bcl-2 AO pharmacokinetics and toxicities
There is some knowledge about the pharmacokinetics
of PS oligonucleotides with intravenous (i.v.), or intra-
peritoneal (i.p.) infusions [6,7]. Degradation is not
marked (15–50%) up to 48 h, when detectable levels in
the tissues are still present. Excretion occurs in the urine
with 30% loss within 24 h. Plasma clearance by both
routes is biphasic with an initial half-life of 15–25 min
and a second half-life, related in part to protein binding,
of 20–40 h, representing elimination from the body. We
have conﬁrmed similar ﬁnding with subcutaneous
delivery of Bcl-2 antisense (G3139) in mice [8]. G3139
has a high-volume distribution due to high protein
binding, particularly to albumin. Organ distribution
varies with good uptake into bone marrow, liver, spleen,
kidney and lymphatics (haematological sites pre-
dominantly), lesser uptake into other tissues and mini-
mal uptake into the central nervous system [8].
Subcutaneous AO infusions prolongs the bioavailability
of the molecule and increase steady-state levels [8,9].
Minimal toxicities, at a dose up to 10 mg/kg/day for 2
weeks, have been administered as an i.v. continuous
infusion, avoiding the potential i.v. bolus toxicities and
possibly providing greater bioavailability [8]. Those
associated with bolus administration are rapid periph-
eral vasodilatation and a transient anticoagulant eﬀect.
Thioate chemistry eﬀects are rapidly reversible and
include mild thrombocytopaenia (dose-dependent) and
mild hyperglycaemia (non-dose-dependent) requiring no
treatment.3. Preclinical Bcl-2 AO therapy in lymphoma
The systemic use of AO has its attractions where it
might be hoped to have a speciﬁc antitumour eﬀect
while avoiding the many non-speciﬁc toxicites caused by
chemotheraputic substances. It is this approach that has
been most beneﬁcial in lymphoma. The Bcl-2 oncogene
has been implicated in the oncogenicity of a wide variety
of haematological malignancies and cancers, including
melanoma, breast, lung and bowel carcinomas. Bcl-2
protein directly prolongs cellular survival by blocking
programmed cell death. Approaches to downregulate
the protein by antisense therapy have been pursued as
an antitumour strategy. Initial attempts to manipulate
the Bcl-2 gene with antisense DNA consisted of trans-
fecting a Bcl-2 antisense sequence in a plasmid into a
human T-cell lymphoma cell line [10]. Transfection with
a combination of Bcl-2 and C-MYC sense plasmids
markedly enhanced the tumorigenicity of this cell line in
a nude mouse model. The Bcl-2 antisense gene reduced
survival of the cell line following growth factor depri-
vation. When Bcl-2 AO was substituted for the anti-
sense gene a similar eﬀect was observed, with reducedF.E. Cotter / EJC Supplements Vol 1 No. 2 (2003) 19–27 21
expression of Bcl-2 protein [11]. In follicular lymphoma
cell lines with high and deregulated Bcl-2 protein levels
due to the t(14;18) translocation, Bcl-2 AO directed at
the open reading frame of Bcl-2, compared with control
sense and nonsense oligonucleotides gave speciﬁc
downregulation of Bcl-2 protein with a subsequent
induction of apoptosis [5]. The AO has little or no eﬀect
on the viability of cell lines not expressing high levels of
Bcl-2, suggesting that the AO is speciﬁcally targeting
cells with high levels of Bcl-2 expression. Down-
regulating Bcl-2 in a cell that is heavily dependent on
Bcl-2 expression for its survival advantage appears to
commit the cell to an apoptotic death even when Bcl-2 is
subsequently upregulated again, suggesting an irrever-
sible process. It has been demonstrated that the AO is
exerting its eﬀect by induction of apoptotic cell death, as
indicated by DNA fragmentation and characteristic
apoptotic bodies. Similar sequence-speciﬁc eﬀects are
seen with Bcl-2 AO on human leukaemia cell lines with
high Bcl-2 expression [10,11].
Using the in vivo lymphoma model from the same cell
line [5], an eﬀect against tumour growth in vivo [5,12]
was also possible with a 2-week infusion at 100 mg daily
achieving a plasma level of approximately 0.1 mM. Both
G3139 and G3854 Bcl-2 AO showed similar eﬃcacy.
G3139 was chosen to pursue an in vivo human study
being shorter by two bases. Sixty mice with lymphoma
were treated with Bcl-2 AO G3139 (sequence 50-
tctcccagcgtgcgccat-3 supplied by Genta, USA) and
showed almost complete abolition of lymphoma in 50
(83%) of the mice; however, disease was still present in
the remaining mice (17%) . Extention of the treatment
to 3 weeks, at the same dose, showed complete eradica-
tion of lymphoma in all animals, even at a PCR level. A
dose response was also established and, at a dose of 300
mg/day for 2 weeks, complete disease eradication was
observed [9]. No abolition of lymphoma was seen in any
other group of controls which produced a similar pat-
tern of disease to untreated mice. The experiments were
also repeated in NOD/SCID mice which have no NK, B
or T cell activity, and similar eﬃcacy was observed. This
is of importance as it has been postulated that some AO
may work through induction of interferon or tumour
necrosis factor released by NK or B cells [13]. As eﬃ-
cacy was seen in mice incapable of producing these
cytokines, it provides further evidence for a direct Bcl-2
AS eﬀect. These results suggest that duration of treat-
ment may be as important as the dosage, and certainly
considerably less antisense is required, to give complete
disease eradication, with a 3-week infusion compared to
2. Having undergone rigorous eﬃcacy, pharmacokinetic
and toxicity studies to complete preclinical evaluation in
partnership with Genta (an antisense research com-
pany, San Diego, USA), these studies have now been
extended into a phase I study for lymphoma patients
with high Bcl-2 expression and who have failed at leasttwo therapy regimens (taking place at The Royal
Marsden Hospital, Sutton, UK).4. A phase I Bcl-2 antisense for lymphoma
Low-grade and follicular non-Hodgkin’s lymphomas
are essentially incurable. They have an indolent course,
initially chemosensitive, but eventually relapsing with
chemoresistant disease. The median survival in the
region 10 years from diagnosis. In the later stages of the
disease, these tumours develop chemoresistance and
often transform to a more aggressive histological
appearance. Intermediate/high grade (aggressive, dif-
fuse) non-Hodgkin’s lymphoma provide a better chance
of long-term survival in the region of 40% with combi-
nation chemotherapy such as CHOP (Cyclopho-
sphamide, Adriamycin, Vincristine, Prednisolone) but
60% will die of their disease having initially responded
to therapy. Bcl-2 expression appears to be a major fac-
tor in therapy failure. As already stated, overexpression
of the Bcl-2 gene results in resistance to programmed
cell death (apoptosis) [14] leading to chemoresistance
[15]. Two recent studies have examined the prognostic
signiﬁcance of Bcl-2 overexpression in patients with
diﬀuse, large B cell lymphoma. In both these studies,
multivariate analyses conﬁrmed the importance of Bcl-2
expression as an independent prognostic marker [16,17].
In low-grade, follicular non-Hodgkin’s lymphoma, Bcl-2
overexpression is seen in virtually all the tumours. High
levels of the Bcl-2 protein expression occur for a number of
reasons, one of these being a t(14;18) translocation. How-
ever, the prognostic signiﬁcance in both low-grade and
more aggressive lymphomas does not lie in the speciﬁc
translocation but in the overexpression of Bcl-2 [17–19].
Therapies based on the molecular biology of the disease
oﬀer an alternative approach which may improve both
response and survival. The preclinical data with Genasense
(G3139 Bcl-2 AO) suggested a logical group of patients
with relapsing lymphoma and high Bcl-2 expression, for a
phase I study to examine the toxicities of such a treatment
[5]. In addition, this group of patients could give some
indication of antilymphoma activity.5. Design of the trial
Patients eligible for the study were required to have
B-cell non-Hodgkin’s lymphoma of any grade that
demonstrated immunohistochemically to overexpress the
Bcl-2 protein in a lymph node biopsy. Patients were also
required to have relapsing disease following completion
of at least two forms of conventional treatment
(including chlorambucil and ﬂudarabine), a life expec-
tancy of more than 12 weeks, normal renal and liver
function, a white blood count greater than 3109/l and22 F.E. Cotter / EJC Supplements Vol 1 No. 2 (2003) 19–27
a platelet count in excess of 100109/l. Toxicity assess-
ment was scored according to the common toxicity cri-
teria (CTC) (NCI, 1988). This included areas of concern
pinpointed in in vitro and animal studies.
The Genasense (Genta Incorporated, USA) was
administered for 2 weeks subcutaneously on the abdo-
men as a continuous infusion using a portable syringe
driver. This directly mimicks the in vivo animal model.
Subcutaneous infusions of PS oligonucleotides may
cause some infusion-site inﬂammation. The infusion
sites were therefore changed when early signs of inﬂam-
mation were observed. Toxicity was monitored for the
initial 48 h of treatment as an inpatient but thereafter as
an outpatient. A single 2-week course of treatment was
given. If there was evidence of response, a second course
was considered. The starting dose was 4.6 mg/m2/day
which was well below the 1/10th LD1O in mice. The
dose was increased by 100% within each patient cohort
unless grade 2 or greater toxicity was observed accord-
ing to the European Organisation for Research and
Treatment of Cancer (EORTC) schema. The maximum
tolerated dose was deﬁned as the dose which causes
grade 3 or 4 toxicity in 50% or more patients. Response
was evaluated from CT scan performed pretreatment, at
weeks 2 (end of infusion) and 6, and classiﬁed using the
World Health Organisation (WHO) criteria. A complete
response (CR) was deﬁned as disappearance of all dis-
ease and a partial response (PR) 50% or greater reduc-
tion in the bidimensional product of measurable disease.
Greater than 25% increase in the bidimensional product
of measurable disease was deﬁned as progressive disease
(PD) and all other states were deﬁned as stable disease
(SD). Additional parameters of lymphoma activity were
serum LDH and the numbers of circulating lymphoma
cells identiﬁed morphologically changes in excess of
20% were considered relevant).
Samples of blood, bone marrow and ﬁne-needle aspi-
rates of lymph nodes were collected at the start of weeks
0, 2 and 6. Mononuclear cells, freshly separated by
Ficoll–Isopaque centrifugation (Lymphoprep;
Nycomed, Norway), were suspended in 10% DMSO
and stored in liquid nitrogen. At the time of analysis,
the samples were ﬁxed in 70% ethanol, incubated with
an antibody to the Bcl-2 protein (DAKO, clone 124)
followed by further incubation with an anti-IgG FITC
second antibody. Bcl-2 protein levels were determined
by ﬂow cytometric analysis of gated lymphocytes.
Within this population, Bcl-2-negative and -positive
cells were identiﬁed. The mean value and standard
deviation were determined by gating on the Bcl-2
population. All samples from a single patient were
labelled simultaneously under the same conditions.
Controls for non-speciﬁc protein expression (patient 3
onwards) were determined by ﬂow cytometry using
incubation with FITC conjugated HLA-A,B,C antibody
(Scrotec).A portion of the lymph node biopsy from patient 6
was disaggregated and 107 cells injected i.p. in to three
non-obese diabetic, severe combined immunodeﬁcient
(NOD/SCID) mice within 24 h of the biopsy. Each
mouse was ﬁtted with a subcutaneous osmotic AZLET
pump which delivers a 2-week infusion. This consisted
of either 0.9% saline, a control reverse sense ollgonu-
cleotide (0.4 mg/kg/day sequence 50-taccgcgtgcgaccctct-
3) or antisense (0.4 mg/kg/day Anticode G3139
sequence) starting on day 1 for 14 days. The proportion
of lymphoma cells in the spleen, liver and bone marrow
was determined using ﬂow cytometry to identify cells
dual labelling for CD45 (conunon leucocyte antigen)
and CD 19 (B cell lymphoma marker).6. Results of the phase I Bcl-2 antisense study
21 patients have been entered into the trial over a
3-year period [20,21] and it has now been completed. All
had been extensively pretreated and had relapsing dis-
ease satisfying the entry criteria for the study. The
patients all had stage IV disease.
6.1. Tolerable toxicity proﬁle
The main aim of a phase I study is to determine the
dose-limiting toxicity in this case for G3139 [20,21]. The
toxicites seen have essentially been minimal as reported
for the ﬁrst 9 patients where 100% dose increments (up
to 2 mg/kg/day for patients 7, 8 and 9) were achieved as
planned [20,21]. The dose was further increased to a
dose slightly in excess of 6 mg/kg/day and, at this dose,
toxicity was seen in the form of throbocytopaenia and
essentially prevented further increases. The course of
treatment did not need to be curtailed due to the
thrombocytopaenia. A reduction in the increment dose
below this level (aprroximately 5 mg/kg/day) for a fur-
ther 3 patients did not result in toxicity. In the few
patients at the higher dose, Bcl-2 oligonucleotide con-
centration has been measured in the region of 1 mM,
although individual variability is seen. A plateau level
has not been reached as rapidly (up to 2 weeks), unlike
the mice where a constant state is reached within 4
days [8]. Interferon and cytokine levels were mon-
itored during the treatment and showed no rise. It is
of note that the non-toxic dose is currently well
within the therapeutic range observed in the animal
models.
6.1.1. Haematological toxicity
The evaluation of haematological toxicities in lym-
phoma with bone marrow disease (commonly present in
progressive low-grade disease) is not easy as it is
required to determine the contribution from the disease
versus the contribution of the AO. Taking this intoF.E. Cotter / EJC Supplements Vol 1 No. 2 (2003) 19–27 23
consideration, there was no antisense-related haemato-
logical toxicity. However, patient 8 developed grade 3
leucopaenia and grade 2 thrombocytopaenia associated
with a haemophilus inﬂuenzae chest infection at the
start of the 2-week treatment infusion. The leucopaenia
and thrombocytopaenia resolved while the antisense
infusion continued following treatment with i.v. anti-
biotics, suggesting a non-oligonucleotide eﬀect. Patient
9 developed grade 2 thrombocytopaenia at the end of
the 2-week drug infusion and, in addition, marked (up
to 31%) eosinophilia were observed. Subsequently, at
week 6, bone marrow inﬁltration and progressive dis-
ease in lymph nodes was observed. The thrombocyto-
paenia and eosinophilia resolved on subsequent
treatment with chemotherapy indicating these eﬀects
were more likely to be due to advancing lymphoma than
the antisense oligonucleotide. Lymphopaenia was pre-
sent in 4 patients (patients 3, 7, 8 and 9) pretreatment
and did not worsen with therapy. The anaemia observed
(in patients 2, 5 and 9) was not dose related and
appeared to be equated with advancing bone marrow
inﬁltration. One of the other areas of concern, when
evaluating toxicity, was that of potential T cell altera-
tions brought about by Bcl-2 downregulation in T cell
development. The CD4:CD8 was carefully monitored
and no signiﬁcant alterations were seen. No abnormal-
ities in coagulation or clotting factors was observed. An
additional area of concern was that of stem-cell sup-
pression, although a role for Bcl-2 has not been
demonstrated in the stem cell. No evidence of treat-
ment-related aplasia has occurred in any of the patients,
although bone marrow biopsies have been regularly
examined in each patient. The dose-limiting toxicity has
been that of a readily reversible thrombocytopaenia.
This occurs towards the ﬁnal few days of the 2-week
infusion only at the highest doses, but has not been
associated with clinical bleeding or bruising. The plate-
let count starts to rise within days of completing the
infusion and the bone marrow contains adequate num-
bers of megakaryocytes. This could be due to increased
peripheral destruction or a direct toxic eﬀect on the
megakaryocyte. It is becoming clear that this is an eﬀect
due to the PS chemistry and not Bcl-2 downregulation as
it has also been observed in subsequent phase I studies
against other gene targets when the dose of oligonucleo-
tide approaches 6 mg/kg/day. It may possibly be avoided
in the future by second-generation backbone chemistries
for the oligonucleotides; however, it must also be noted
that this dose is well above that required for theraputic
eﬃcacy and downregulation of the target RNA and
protein.
6.1.2. Non-haematological toxicity
The G3139 has been well tolerated and the non-
haematological toxicities are shown in [20,21]. Of those
seen, they can be ascribed primarily to the PS chemistryand not to the eﬀects of Bcl-2 downregulation. All
patients had a transient rise in non-fasting blood glu-
cose levels, observed within 24 h of starting the infusion.
None exceeded 12 mmol/l and blood glucose levels were
not dose related and returned to normal after stopping
the therapy. No intervention was required. Similar
ﬁndings have been documented in another PS human
trials targeting P53 [22]. Some of the patients developed
an infection, none of which could be directly attributed
to the antisense therapy. The other signiﬁcant toxicity
directly related to antisense therapy was a local skin
reaction surrounding the infusion site. In 19 patients,
this simply required resiting the line site every 3–4 days.
However, 2 patients suﬀered a local inﬂammatory reac-
tion which became unacceptably painful about 12 h
after starting treatment. A skin biopsy from the
inﬂamed area demonstrated increased inﬁltration of T
lymphocytes. Despite several site changes and dilution
of drug concentration by 50%, the inﬂammation per-
sisted and treatment could not to be continued. 2
patients treated subsequently at these dose levels and 3
with a 100% dose increment did not experience the
same degree of reaction. Patients in i.v. phase I studies
with G3139 have not experiencied inﬂammatory or
allergic reactions to the oligonucleotide. It is possible
that the skin response is due to a local high concen-
tration of the oligonucleotide at the site of injection
leading to inﬂammation.
6.2. Evidence for eﬃcacy
Unlike chemotherapy responses, which are usually
rapid and maximal within a week, the eﬀect of Bcl-2 AO
appears to be slower and more prolonged in duration,
with continued reduction in lymophoma bulk in excess
of 6 weeks from the end of the infusion [20,21]. The
most impressive response was seen in patient 8 where
no lymph node masses larger than 1 cm by 6 weeks
and had achieved a response in all lymph node sites,
the largest pretreatment lymph node measuring
2.52.0 cm. This patient remains in remission 3 years
after starting treatment without having further therapy.
No other patients achieved CR; however, 2 have had
partial responses, a further 8 have had a durable sta-
bilisation of disease and at least 2 of this latter group
have shown symptomatic improvement. For example,
within 48 h of starting treatment, patient 1 had resolu-
tion of sweats and pruritus which lasted 3 weeks. On
retreatement at the same dose, this patient again had
resolution of the sweats and pruritus again. Patient 8’s
lymphoma-related alcohol intolerance resolved such
that he was able to drink alcohol for the ﬁrst time in 2
years. Of the ﬁrst 9 patients evaluated, 2 out of 3
patients had a reduction in their circulating lymphoma
cells (patients 2 and 6), 4 out of 9 patients had a reduc-
tion in their scrum LDH levels (patients 1, 2, 6 and 8).24 F.E. Cotter / EJC Supplements Vol 1 No. 2 (2003) 19–27
The full evaluation of all the patients has not yet been
completed, but it is clear that there is solid evidence of
therapeutic eﬃcacy with only a 2-week infusion of the
Bcl-2 antisense. For a phase I study, this represents a
successful agent for further evaluation in a phase II trial
to concentrate primarily on eﬃcacy.
6.3. Bcl-2 expression
Technically and ethically, it is diﬃcult without ready
access to tumour material for the evaluation of Bcl-2
expresssion. It was felt that circulating lymphoma cells
could oﬀer this opportunity as well as ﬁne-needle aspi-
rates from lymph nodes when readily accessible, without
potentially endangering the patients’ well being. Over
the treatment period and the subsequent 4 weeks, Bcl-2
levels were measured by ﬂow cytometry in peripheral
blood samples containing circulating lymphoma cells.
Bcl-2 levels were speciﬁcally reduced in the lymph node
aspirates for those patients where they were readily
accessible.
6.4. Further treatment
8 out of the ﬁrst 9 patients have gone on to receive
further chemotherapy with a variety of regimens. 6 out
of the 8 patients treated with further chemotherapy
have achieved PR using chemotherapy for which
response had been poor previously. Patient 9 was trea-
ted with the chemotherapy regimen ChlVPP (Chlor-
ambucil, Vinblastine, Procarbazine, Prednisolone) 5
weeks after ﬁnishing antisense treatment and unusually
developed complete alopecia.
6.5. Phase II and III studies with Genasense
Genasense has now been used in a number of clinical
settings including phase 2 studies in combination with
chemotherapy. This works on the basis that lowering
the Bcl-2 protein with the Genasense leads to sensitisa-
tion of the malignant cells to chemotherapy. A number
of solid tumours, including malignant melanoma, breast
cancer, prostate cancer and small-cell lung cancers, have
shown evidence for synergy. Genasense has recently
received fast track and orphan drug designation for the
treatment of myeloma, chronic lymphatic leukaemia
(CLL) and acute myeloid leukaemia. At the ASH 2001
meeting, Susan O’Brien from the MD Anderson Hospi-
tal in Texas presented some preliminary patient studies
with Genasense as a single agent with good eﬃcacy at a
dose of 3 mg/kg/day. Our own group presented data
showing synergism between Bcl-2 antisense and Rituxi-
mab in CLL cells. Multicentre studies have now been
commenced for both CLL and myeloma combining the
Genasense with chemotherapy. The stage III study of
Genasense with chemotherapy for malignant melanomais nearing completion. A phase II study for mantle cell
lymphoma will also commence shortly in our institution.7. Conclusions
In vitro and in vivo studies culminating in a human
phase I study with Bcl-2 antisense (Genasense) to inhibit
expression of Bcl-2 have demonstrated good eﬃcacy
with low toxicity [20,21]. Tumour regressions, improve-
ment in the laboratory parameters, symptom improve-
ment together with downregulation of target protein
expression [20,21] has also been achieved. These results,
although very preliminary, certainly match a good
chemotheraputic drug [20]. 3 patients had evidence of
tumour shrinkage on the CT scanning with 1 patient
maintaining this improvement 3 years on. The combi-
nation of this evidence supports the theory that Bcl-2
antisense oligonucleotides have antilymphoma activity
[20,21]. In vitro studies demonstrate speciﬁc reduction in
mRNA, protein expression and induction of apoptosis
using Bcl-2 antisense [5]. For the ﬁrst time, this study
demonstrates evidence of downregulation of the target
protein in humans and the parallel animal model pro-
vides evidence of a sequence-speciﬁc antilymphoma
eﬀect. It was observed that 6 out of 8 patients who were
treated with chemotherapy following antisense treat-
ment went on to achieve a partial remission. Patient 9
developed complete alopecia with ChlVPP, a treatment
regimen with a documented 0.5% incidence of this side-
eﬀect [23]. It is known that Bcl-2 levels in the hair folli-
cle are normally high [24] and Bcl-2 knock out mice
develop abnormalities in hair pigmentation [25,26].
These results suggest that Bcl-2 antisense, when given
prior to chemotherapy, may have a sensitising eﬀect.
Potential uses of Bcl-2 antisense extend beyond the ﬁeld
of lymphoma as overexpression of Bcl-2 is seen in
breast, lung, melanoma, leukaemia, prostate, gastric
and colorectal tumours. This is speculative as it was
outside the study parameters, but is currently being
addressed and may have relevance to further human
trial designs. A summary of studies currently taking
place with Genasense is shown in Table 1. Having
shown it is possible to reduce Bcl-2 expression with
Bcl-2 antisense oligonucleotide, these studies (including
a phase II study for lymphoma in our institution) is
aimed at using the lowered Bcl-2 antisense to increase
sensitivity to chemotherapy.
An important aim of the phase I study was to estab-
lish toxicity of Bcl-2 antisense oligonucleotides. A max-
imum tolerated dose has been established at 4 mg/kg/
day. Concerns about potential toxicity came from a
number of sources. Mouse toxicity data using this com-
pound demonstrated myocardial and liver necrosis,
splenomegaly and deaths at high dosages (50 mg/kg/
day). The dose levels at present are more than 10-foldF.E. Cotter / EJC Supplements Vol 1 No. 2 (2003) 19–27 25
less than those at which toxicities were observed in mice.
Primate studies revealed no clinical toxicity and autopsy
revealed only mild injection site inﬂammation and non-
speciﬁc pathological changes within the kidneys at doses
up to 10 mg/kg/day for 2 weeks [7]. Primate studies
using high doses of other PS compounds demonstrated
hypotension and deaths if the drugs were give as a rapid
i.v. bolus but not when given as an infusion. Further-
more, the hypotensive events were not sequence-related
[27]. Another human study, using a 20-base fully phos-
phorothioated oligonuelcotide targeted against p53 in
patients with acute myeloid leukaemia and myelodys-
plastic syndrome at doses up to 6 mg/kg/day as an i.v.
infusion, demonstrated no compound-related toxicity
[22]. There was concern that this compound might have
direct a sequence-related eﬀect on cells which express
high Bcl-2 levels under normal conditions, but this has
not so far been observed. The memory B cells, mature
(CD4+ and CD8+) T cells, neuronal tissue and intest-
inal mucosa have high Bcl-2 levels. Bone marrow stem
cells do not normally overexpress Bcl-2 and another
member of the Bcl-2 family, Bcl-XL, appears to be of
greater importance here, so adverse eﬀects against the
stem cells were considered unlikely [28]. It also seems
unlikely that neuronal tissue would be damaged as oli-
gonucleotides do not cross the blood-brain barrier. In
addition, Bcl-2 knock out mice in which both copies of
the Bcl-2 gene have been deleted by recombinant DNA
techniques are viable without neurological deﬁcit, sug-
gesting that Bcl-2 is not of prime importance to the stem
cells or neuronal tissue. However, the knock out mice
do subsequently develop lymphopaenia, apoptotic
involution in the thymus and spleen, polycystic kidneys,
grey hair in the second follicle cycle [25,26] and dis-
torted small intestine [26]. In practice, and at the current
dose levels, major Bcl-2 sequence speciﬁc toxicities do
not occur.
The only signiﬁcant treatment-related toxicity is
almost certainly PS-related. This was an inﬂammatory
response at the injection site. In 2 patients, this was
severe enough for the treatment to be stopped. The
severity of reaction, however, was not seen in other
patients, even at higher doses. Transient non-fasting
hyperglycaemia has also been observed during the
treatment period. This had no clinical implications but
has also been noted in a recently published report of
antisense treatment against p53, suggesting it may be
related to the PS backbone chemisty, and does not
appear to be dose-related [22].
The potential uses of Bcl-2 antisense oligonucleotides
are many. They include a single-agent use, treatment of
minimal residual disease or ex vivo purging of bone
marrow or peripheral stem-cell harvests. Potentially, the
most important application may be to overcome
chemoresistance. With care, novel therapies based on
the biology of the malignant cell may be determined ona scientiﬁc basis and may help improve the treatment of
patients with these diseases. Gene silencing by antisense
oligonucleotides has a role to play as demonstrated in
lymphomas.Acknowledgements
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